Veloxis' Tacrolimus Clears FDA For Narrower Population Following Court Loss

Envarsus XR, a once-daily version of the immunosuppressant, is approved for kidney transplant patients seeking to convert from twice-daily formulations; a claim for use in newly transplanted, 'de novo' patients was blocked by Astellas' three-year exclusivity on Astagraf.